Harry J. M. Groen, MD, PhD; University Medical Center Groningen 5Live #ASCO20
4:19
Key insights on Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non–small-cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study.
Non Small Cell Lung Cancer
Harry J. M. Groen, MD, PhD; University Medical Center Groningen 5Live #ASCO20
Key insights on Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non–small-cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study.
Non Small Cell Lung Cancer Similar Videos
Similar Videos
